Mesoblast Limited

NASDAQ:MESO

Biotechnology

Healthcare
$11.64 +1.86%

+$0.26 today

Market cap
$1.51B
Beta
0.79
P/E (TTM)
-23.6
EPS (TTM)
-$0.06
52W Low $9.88High $21.50

Volume 0.13M

Average 0.21M

MESO Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Mesoblast LimitedNASDAQ: MESO

Weighted Avg Shares · Q4 FY2026 · quarter ended Jun 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q4 FY2026 weighted avg shares of 129.78M shares rose 1.9% year over year, behind the +7.2% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +15.6% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.9% toward the trailing-twelve-month pace of +7.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
129.78M+0.0% QoQ
Last fiscal yearJun 2026
129.49M+7.2% YoY
LTMJun 2026
129.46M+7.2% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.9%——
1 year+7.2%——
3-year CAGR+15.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2026
129.49M USD
Year-over-year change
+7.2%
4-year CAGR
+17.4%

Weighted Avg Shares vs competitors

How MESO compares with its peers on the latest reported figures

  • MESO's LTM Jun 2026 weighted avg shares of 129.46M shares is the 3rd highest of the 6 companies compared; the peer median is 119.09M shares.
  • Its year-over-year change of +7.2% is the 4th highest of 6, against a peer median of +13.6%.
  • Over three fiscal years its annual growth of +15.6% compares with a peer median of +10.7%.
MESO Competitors Peer median
Weighted Avg Shares for MESO and competitors
Company Period LTM YoY 3-year CAGR
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026233.09M +16.0%+10.7%
LEGNLegend Biotech CorporationLTM Sep 2026185.87M +1.7%+5.0%
MESOMesoblast LimitedLTM Jun 2026129.46M +7.2%+15.6%
FATEFate Therapeutics, Inc.LTM Mar 2026119.09M +1.0%+7.1%
CAPRCapricor Therapeutics, Inc.LTM Mar 202649.43M +35.6%+23.7%
CELUCelularity Inc.LTM Dec 202524.87M +13.6%+22.3%
Peer median (excluding MESO) 119.09M+13.6%+10.7%

Competitors are the stored peer set for MESO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Revenue10.21M7.5M5.9M17.2M120.79M
Cost of Revenue63.57M54.92M41.07M5.13M19.21M
Gross Profit(53.36M)(47.42M)(35.17M)12.07M101.58M
Gross Margin-522.6%-632.2%-595.9%70.2%84.1%
Research & Development32.82M27.19M25.35M34.81M97.94M
Selling, General & Admin57.97M53.11M23.63M39.31M55.13M
Operating Expenses90.79M76.79M48.98M74.51M153.08M
Depreciation & Amortization4.38M4.11M1.9M6.4M8.62M
EBITDA(76.57M)(58.55M)(56.08M)(73.66M)(42.88M)
EBITDA Margin-749.9%-780.6%-950.1%-428.3%-35.5%
Operating Income(80.57M)(69.29M)(84.15M)(62.44M)(51.5M)
Operating Margin-789.1%-923.7%-1425.7%-363.1%-42.6%
Interest Income0831K1.82M3.55M3.93M
Interest Expense17.29M19.44M20.66M22.93M23.95M
Other Income / Expenses(10.48M)(12.81M)(4M)(39.37M)(5.64M)
Income Before Tax(91.59M)(82.1M)(88.15M)(101.81M)(57.14M)
Pre-Tax Margin-896.9%-1094.5%-1493.5%-592.0%-47.3%
Income Tax Expense(239K)(212K)(191K)330K615.74K
Net Income(91.35M)(81.89M)(87.96M)(102.14M)(57.76M)
Net Margin-894.6%-1091.7%-1490.3%-593.9%-47.8%
EPS (Basic)(1.30)(0.98)(0.89)(0.84)(0.45)
EPS (Diluted)(1.30)(0.98)(0.89)(0.84)(0.45)
Weighted Avg Shares68.27M83.77M98.67M120.78M129.49M
Weighted Avg Shares (Diluted)68.29M83.93M98.67M120.78M129.49M

Mesoblast Limited

NASDAQ:MESO

Intrinsic Alpha fair value

Locked

Current Price

$11.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.